RU2644214C2 - СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 - Google Patents

СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 Download PDF

Info

Publication number
RU2644214C2
RU2644214C2 RU2014142990A RU2014142990A RU2644214C2 RU 2644214 C2 RU2644214 C2 RU 2644214C2 RU 2014142990 A RU2014142990 A RU 2014142990A RU 2014142990 A RU2014142990 A RU 2014142990A RU 2644214 C2 RU2644214 C2 RU 2644214C2
Authority
RU
Russia
Prior art keywords
antibody
cxcr5
light
amino acid
preparation
Prior art date
Application number
RU2014142990A
Other languages
English (en)
Russian (ru)
Other versions
RU2014142990A (ru
Inventor
Дирк ЮСИНЕР
Ахмед ЮССЕФ
Анника ХАГЕНДОРФ
Мартина КИРШ
Сабрина РАГГЕБЕРГ
Юлия ШНИДЕРС
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of RU2014142990A publication Critical patent/RU2014142990A/ru
Application granted granted Critical
Publication of RU2644214C2 publication Critical patent/RU2644214C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2014142990A 2012-03-26 2013-03-26 СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 RU2644214C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615539P 2012-03-26 2012-03-26
US61/615,539 2012-03-26
FR1351013 2013-02-06
FR1351013 2013-02-06
PCT/US2013/033881 WO2013148686A2 (en) 2012-03-26 2013-03-26 Stable igg4 binding agent formulations

Publications (2)

Publication Number Publication Date
RU2014142990A RU2014142990A (ru) 2016-05-20
RU2644214C2 true RU2644214C2 (ru) 2018-02-08

Family

ID=49261390

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014142990A RU2644214C2 (ru) 2012-03-26 2013-03-26 СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4

Country Status (7)

Country Link
EP (3) EP2830658B1 (enExample)
JP (1) JP6265970B2 (enExample)
BR (2) BR112014023952B1 (enExample)
CA (3) CA2868401C (enExample)
PL (1) PL2830658T3 (enExample)
RU (1) RU2644214C2 (enExample)
WO (1) WO2013148686A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
TWI760345B (zh) * 2016-07-05 2022-04-11 法商賽諾菲公司 抗體調配物
DK3481420T3 (da) * 2016-07-05 2025-11-03 Sanofi Sa Antistofformuleringer
US20190359930A1 (en) * 2016-11-11 2019-11-28 Bayer Aktiengesellschaft Method for sampling fluid streams for monitoring contaminants in a continuous flow
SMT202500120T1 (it) * 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
GB201701194D0 (en) * 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
JP2024502825A (ja) * 2020-12-30 2024-01-23 エーマックス バイオ， インコーポレイテッド 抗体の局所的延長放出

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
WO2008157409A1 (en) * 2007-06-14 2008-12-24 Elan Pharmaceutical, Inc. Lyophilized immunoglobulin formulations and methods of preparation
WO2009032661A1 (en) * 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
SMP200800064B (it) * 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
WO2008157409A1 (en) * 2007-06-14 2008-12-24 Elan Pharmaceutical, Inc. Lyophilized immunoglobulin formulations and methods of preparation
WO2009032661A1 (en) * 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ISHIKAWA T. et al., Influence of pH on Heat-Induced Aggregation and Degradation of Therapeutic Monoclonal Antibodies, Biol Pharm Bull. 2010, Vol.33, No.8, pp.1413-7. *
ISHIKAWA T. et al., Influence of pH on Heat-Induced Aggregation and Degradation of Therapeutic Monoclonal Antibodies, Biol Pharm Bull. 2010, Vol.33, No.8, pp.1413-7. LI Y. et al., High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies, J Pharm Sci. 2011 Jun, Vol.100, No.6, pp.2120-35. СЕДЫШЕВ С.Х. и др., IgG4-связанное системное заболевание. Современный взгляд на "старые" болезни, Научно-практическая ревматология, 2012, т.54, No.5, стр.64-72. *
LI Y. et al., High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies, J Pharm Sci. 2011 Jun, Vol.100, No.6, pp.2120-35. *
СЕДЫШЕВ С.Х. и др., IgG4-связанное системное заболевание. Современный взгляд на "старые" болезни, Научно-практическая ревматология, 2012, т.54, No.5, стр.64-72. *

Also Published As

Publication number Publication date
BR112014023952A2 (pt) 2017-07-18
EP2830658A2 (en) 2015-02-04
WO2013148686A2 (en) 2013-10-03
JP6265970B2 (ja) 2018-01-24
PL2830658T3 (pl) 2019-02-28
CA3123252A1 (en) 2013-10-03
WO2013148686A3 (en) 2013-11-28
JP2015514090A (ja) 2015-05-18
CA2868401C (en) 2021-08-24
CA3204402A1 (en) 2013-10-03
RU2014142990A (ru) 2016-05-20
EP3431104A1 (en) 2019-01-23
BR122019026701B1 (pt) 2023-01-24
BR112014023952B1 (pt) 2023-01-24
EP2830658B1 (en) 2018-10-10
EP4527855A3 (en) 2025-06-11
CA2868401A1 (en) 2013-10-03
EP3431104B1 (en) 2026-07-22
EP4527855A2 (en) 2025-03-26
CA3123252C (en) 2023-08-22

Similar Documents

Publication Publication Date Title
EP2830658B1 (en) Stable igg4 binding agent formulations
US10525130B2 (en) Stable IGG4 based binding agent formulations
US12629420B2 (en) CXCR5 antibody formulations
US20230115267A1 (en) Pharmaceutical liquid composition having increased stability
US20240392021A1 (en) Pharmaceutical formulations containing anti-ox40l antibodies
TWI760345B (zh) 抗體調配物
JP6820823B2 (ja) 安定なＩｇＧ４に基づく結合剤の製剤

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200327